Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, raised $12 million by offering 1.5 million shares at $8, below the range of $10 to $12. Aldeyra Therapeutics plans to list on the NASDAQ under the symbol ALDX. Aldeyra Therapeutics initially filed confidentially on 12/4/2013. Aegis Capital acted as lead manager on the deal.
